Acutus Medical Announces Restructuring and Preliminary, Unaudited Fourth Quarter and Full Year 2021 Revenue

3 years ago

CARLSBAD, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management…

Bavarian Nordic Appoints Russell Thirsk as new Chief Operating Officer

3 years ago

COPENHAGEN, Denmark, January 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the appointment of Russell Thirsk as Executive…

Mainz Biomed Engages DCN Dx to Support Clinical Study Evaluating Novel mRNA Biomarkers for Potential Integration into ColoAlert

3 years ago

Results of European study potentially incorporated into U.S. regulatory strategy for FDA approval Opportunity for ColoAlert to become the gold…

Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis

3 years ago

Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis Dupixent is the first and…

Bone Therapeutics provides fourth quarter 2021 business update and 2022 outlook

3 years ago

REGULATED INFORMATION Recruitment for ALLOB tibial facture Phase IIb study ongoing and on schedule to release topline data in Q1…

Awakn Life Sciences Signs MOU with Maps

3 years ago

Agreement to Explore a Partnership for MDMA-Assisted Therapy for Treatment of Alcohol Use Disorder in EuropeToronto, Ontario--(Newsfile Corp. - January…

Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board

3 years ago

Oakville, Ontario--(Newsfile Corp. - January 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a…

CareView Communications Executes Agreement With a Large For-Profit Health System Division

3 years ago

LEWISVILLE, Texas--(BUSINESS WIRE)--CareView Communications, Inc. (“CareView” or the “Company”) (OTCQB: CRVW), a technology provider to the healthcare industry, today announced…

Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology

3 years ago

Financing co-led by venBio Partners & Qiming Venture Partners USA with participation from strong syndicate of new and existing investors…

Tempo Automation, Inc. Secures $200 Million Convertible Note Financing Led by Oaktree

3 years ago

SAN FRANCISCO--(BUSINESS WIRE)--Tempo Automation, (“Tempo” or the “Company”), a leading software-accelerated electronics manufacturer, and ACE Convergence Acquisition Corp. (“ACE”) (Nasdaq:…